EP2091969A4 - Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und damit im zusammenhang stehende verfahren - Google Patents

Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und damit im zusammenhang stehende verfahren

Info

Publication number
EP2091969A4
EP2091969A4 EP07812601A EP07812601A EP2091969A4 EP 2091969 A4 EP2091969 A4 EP 2091969A4 EP 07812601 A EP07812601 A EP 07812601A EP 07812601 A EP07812601 A EP 07812601A EP 2091969 A4 EP2091969 A4 EP 2091969A4
Authority
EP
European Patent Office
Prior art keywords
polypeptides
related methods
cytotoxic properties
reduced increased
antiinflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07812601A
Other languages
English (en)
French (fr)
Other versions
EP2091969A2 (de
Inventor
Falk Nimmerjahn
Yoshikatsu Kaneko
Jeffrey V Ravetch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/041791 external-priority patent/WO2007055916A2/en
Priority claimed from PCT/US2007/008396 external-priority patent/WO2007117505A2/en
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of EP2091969A2 publication Critical patent/EP2091969A2/de
Publication of EP2091969A4 publication Critical patent/EP2091969A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP07812601A 2006-10-27 2007-07-03 Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und damit im zusammenhang stehende verfahren Ceased EP2091969A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2006/041791 WO2007055916A2 (en) 2005-11-07 2006-10-27 Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
PCT/US2007/008396 WO2007117505A2 (en) 2006-04-05 2007-04-03 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PCT/US2007/072771 WO2008057634A2 (en) 2006-10-26 2007-07-03 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Publications (2)

Publication Number Publication Date
EP2091969A2 EP2091969A2 (de) 2009-08-26
EP2091969A4 true EP2091969A4 (de) 2010-05-12

Family

ID=39367532

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07812601A Ceased EP2091969A4 (de) 2006-10-27 2007-07-03 Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und damit im zusammenhang stehende verfahren

Country Status (3)

Country Link
EP (1) EP2091969A4 (de)
AU (1) AU2007317755A1 (de)
WO (1) WO2008057634A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
BRPI0910091A2 (pt) 2008-03-27 2017-05-30 Novozymes As processo para produzir um produto de fermentação
JP2011517960A (ja) 2008-04-22 2011-06-23 ザ ロックフェラー ユニバーシティー 抗炎症化合物の識別方法
EP2233499A1 (de) 2009-03-26 2010-09-29 CSL Behring AG Antikörperzusammensetzung mit veränderter Fab-Sialylierung
EP2233502A1 (de) * 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
US9187568B2 (en) 2009-05-07 2015-11-17 Stallergenes S.A. Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
SG177764A1 (en) 2009-07-30 2012-03-29 Hoffmann La Roche Enzymatic antibody processing
US20130058917A1 (en) 2010-05-07 2013-03-07 Fabian Käsermann Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
WO2012012590A2 (en) 2010-07-23 2012-01-26 Novozymes A/S Processes for producing fermentation products
BR112013007293A2 (pt) 2010-10-05 2016-06-14 Hoffmann La Roche anticorpos contra a tweak de seres humanos e suas utilizações
JP2014503495A (ja) * 2010-11-15 2014-02-13 バイオジェン アイデック インコーポレイテッド 過負荷結合および溶出クロマトグラフィによる選択生成物アイソフォームの富化および濃縮
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9650433B2 (en) 2011-05-20 2017-05-16 Momenta Pharmaceuticals, Inc. Modified glycoproteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9365881B2 (en) 2011-10-05 2016-06-14 Hoffmann-La Roche Inc. Process for antibody G1 glycoform production
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9663581B2 (en) 2012-04-25 2017-05-30 Momenta Pharmaceuticals, Inc. Modified glycoproteins
WO2014018747A2 (en) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2900264A4 (de) * 2012-09-26 2016-05-25 Momenta Pharmaceuticals Inc Glykoproteinzubereitungen
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3058084A4 (de) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylierte glycoproteine
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
EA202091521A1 (ru) 2017-12-19 2020-10-22 Дзе Рокфеллер Юниверсити ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039488A1 (en) * 1995-06-06 1996-12-12 Genentech, Inc. Process for controlling sialylation of proteins produced by mammalian cell culture
WO2000063403A2 (en) * 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
WO2004058944A2 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
WO2007005786A2 (en) * 2005-06-30 2007-01-11 Centocor, Inc. Methods and compositions with enhanced therapeutic activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039488A1 (en) * 1995-06-06 1996-12-12 Genentech, Inc. Process for controlling sialylation of proteins produced by mammalian cell culture
WO2000063403A2 (en) * 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
WO2004058944A2 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
WO2007005786A2 (en) * 2005-06-30 2007-01-11 Centocor, Inc. Methods and compositions with enhanced therapeutic activity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DALZIEL MARTIN ET AL: "Lectin analysis of human immunoglobulin G N-glycan sialylation", GLYCOCONJUGATE JOURNAL, vol. 16, no. 12, December 1999 (1999-12-01), pages 801 - 807, XP002575135, ISSN: 0282-0080 *
JASSAL R ET AL: "Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 17 AUG 2001, vol. 286, no. 2, 17 August 2001 (2001-08-17), pages 243 - 249, XP002574380, ISSN: 0006-291X *
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075 *
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1129594 *
NIMMERJAHN FALK ET AL: "The antiinflammatory activity of IgG: the intravenous IgG paradox", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 204, no. 1, January 2007 (2007-01-01), pages 11 - 15, XP002575137, ISSN: 0022-1007 *
RAJU T SHANTHA ET AL: "Glycoengineering of therapeutic glycoproteins: In vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 40, no. 30, 31 July 2001 (2001-07-31), pages 8868 - 8876, XP002461128, ISSN: 0006-2960 *
SCALLON ET AL: "Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 7, November 2006 (2006-11-01), pages 1524 - 1534, XP005792683, ISSN: 0161-5890 *
See also references of WO2008057634A2 *
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED .ALPHA.-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 263, no. 10, 5 April 1988 (1988-04-05), pages 4576 - 4585, XP002575136, ISSN: 0021-9258 *
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED ALPHA-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 10, 1988, pages 4576 - 4585, XP002575136, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008057634A2 (en) 2008-05-15
EP2091969A2 (de) 2009-08-26
AU2007317755A1 (en) 2008-05-15
WO2008057634A3 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
BRPI0719369A2 (pt) Porta-prótese e aplicações do mesmo
GB2446843B (en) Amplifier circuit and methods of operation thereof
EP1967207A4 (de) Hemmer der zytotoxischen t-zell-induktion
EP2010566A4 (de) Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und entsprechende verfahren
DK3263589T5 (da) Peptidsekvenser og sammensætninger
EP1987184A4 (de) Kohlenstoff-kohlenstoff-elemente und herstellungsverfahren dafür
SI2084151T1 (sl) Substituirani dihidropirazoloni za zdravljenje kardiovaskularnih in hematoloških bolezni
EP2007877A4 (de) Verfahren für kompakte aggregation von hautzellen
DK2063907T3 (da) Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater
EP2038947A4 (de) Fluidgehäuse und diesbezügliche verfahren
DE602007010272D1 (de) Parkhilfevorrichtung und parkhilfeverfahren
DK2865361T3 (da) Tåreimplantater og tilhørende fremgangsmåder
EP2197380A4 (de) Elektrochirurgisches instrument und verfahren
DE602007010981D1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
DE602007010852D1 (de) Element mit magnetoresistivem Effekt und Herstellungsverfahren dafür
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
ZA200806288B (en) Rage fusion proteins and methods of use
EP1991565A4 (de) Chimäre shigatoxoid-proteine
IL197543A0 (en) Molecular switches and methods for their use
DK1989220T3 (da) HIV-fusionsinhibitorpeptider med forbedrede biologiske egenskaber
EP2066174A4 (de) Zusammensetzungen mit alpha-1-antitrypsin und verwendungsverfahren dafür
DK2081937T3 (da) Triazolopyridazin-proteinkinasemodulatorer
DK2099304T3 (da) Carboranylporfyriner og anvendelser deraf
EP1951050A4 (de) Therapeutische zusammensetzungen und verfahren
DK2023668T3 (da) Høreapparat med visualiserede psykoakustiske variable og tilsvarende fremgangsmåde

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090519

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAVETCH, JEFFREY V.

Inventor name: NIMMERJAHN, FALK

Inventor name: KANEKO, YOSHIKATSU

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE ROCKEFELLER UNIVERSITY

A4 Supplementary search report drawn up and despatched

Effective date: 20100414

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135408

Country of ref document: HK

17Q First examination report despatched

Effective date: 20100719

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135408

Country of ref document: HK